TB-500 (Thymosin Beta-4 Fragment) for ALS (Amyotrophic Lateral Sclerosis): Evidence Level Assessment

By Insight Swarm Research Team, Medical Advisor: Nikhil Joshi, MD, FRCPC

TB-500 (Thymosin Beta-4 Fragment) for ALS (Amyotrophic Lateral Sclerosis): Evidence Level Assessment

Understanding the evidence level for any compound is essential for making informed decisions. This page provides a structured evidence assessment for TB-500 (Thymosin Beta-4 Fragment) in the context of ALS (Amyotrophic Lateral Sclerosis), following evidence-based medicine standards. This is a research summary — not medical advice.

Evidence Hierarchy Overview

Evidence in medicine is evaluated on a hierarchy from strongest to weakest:

  1. Level 1: Systematic reviews and meta-analyses of RCTs
  2. Level 2: Randomized controlled trials (RCTs)
  3. Level 3: Non-randomized controlled trials
  4. Level 4: Case-control and cohort studies
  5. Level 5: Case reports and expert opinion
  6. Preclinical: Animal and cell culture studies (not sufficient for clinical decisions)

Current Evidence Classification: TB-500 (Thymosin Beta-4 Fragment) + ALS

Evidence level: Animal studies only; no peer-reviewed human clinical trials

This evidence level reflects direct research on TB-500 (Thymosin Beta-4 Fragment) in ALS contexts.

Mechanistic Evidence

Mechanistic plausibility does not equal clinical efficacy, but it helps contextualize why researchers investigate compounds. TB-500 (Thymosin Beta-4 Fragment) operates via: Actin sequestration and cell migration promotion; angiogenesis; anti-inflammatory; tissue repair

This mechanism has documented relevance to ALS biology.

What This Evidence Level Means for Patients

An evidence level of "Animal studies only; no peer-reviewed human clinical trials" means:

  • Treatment decisions should not be based solely on this evidence
  • Enrollment in clinical trials (if available) may be the highest-evidence option
  • Compassionate use or off-label consideration requires careful risk/benefit analysis with your neurologist or ALS specialist
  • The absence of strong evidence does not mean the compound doesn't work — it means we don't yet know

How Evidence Levels Evolve

The evidence for TB-500 (Thymosin Beta-4 Fragment) in ALS may improve over time as more clinical trials are completed. Monitor ClinicalTrials.gov for emerging studies. Evidence levels are not permanent — they reflect the current state of published research.

Medical Disclaimer: This page summarizes published research and is not medical advice. Never start, stop, or change any treatment based on information found online. Always consult qualified healthcare professionals before making treatment decisions.

Get a personalized AI-generated research report at insightswarm.ai.

Frequently Asked Questions

What grade of evidence exists for TB-500 (Thymosin Beta-4 Fragment) in ALS?

The current evidence classification is: Animal studies only; no peer-reviewed human clinical trials. This is based on the available published literature as of 2026. Evidence grades can change as new clinical trials are completed and published.

Is the evidence strong enough to consider TB-500 (Thymosin Beta-4 Fragment) for ALS?

Whether the current evidence level (Animal studies only; no peer-reviewed human clinical trials) is sufficient to consider TB-500 (Thymosin Beta-4 Fragment) for your specific ALS case is a clinical decision that requires your neurologist or ALS specialist's assessment of your individual circumstances, risk tolerance, and available alternatives.

Are there clinical trials that could improve the evidence for TB-500 (Thymosin Beta-4 Fragment) in ALS?

To find active trials: search ClinicalTrials.gov for 'TB-500 (Thymosin Beta-4 Fragment)' as intervention. Trial participation is how evidence levels improve over time. Ask your neurologist or ALS specialist whether trial enrollment might be appropriate for your situation.